Next Article in Journal
Acyclovir-Loaded Chitosan Nanospheres from Nano-Emulsion Templating for the Topical Treatment of Herpesviruses Infections
Next Article in Special Issue
Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems
Previous Article in Journal
Material Considerations for Fused-Filament Fabrication of Solid Dosage Forms
Previous Article in Special Issue
Design, Optimization and Characterization of a Transfersomal Gel Using Miconazole Nitrate for the Treatment of Candida Skin Infections
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Pharmaceutics 2018, 10(2), 45; https://doi.org/10.3390/pharmaceutics10020045

Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges

1
Department of Neurosurgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA
2
Faculty of Neurosurgery, California Institute of Neuroscience, Thousand Oaks, CA 91360, USA
3
Faculty of Medicine and Health Sciences, An-Najah National University, Nablus 11941, Palestine
4
Department of Neurosurgery, University of South Alabama, Mobile, AL 36688, USA
*
Author to whom correspondence should be addressed.
Received: 5 March 2018 / Revised: 3 April 2018 / Accepted: 4 April 2018 / Published: 9 April 2018
(This article belongs to the Special Issue Lipid-Based Dosage Form)
View Full-Text   |   Download PDF [1105 KB, uploaded 3 May 2018]   |  

Abstract

Glioblastoma is the most common, malignant primary tumor of the central nervous system. The average prognosis for life expectancy after diagnosis, with the triad of surgery, chemotherapy, and radiation therapy, is less than 1.5 years. Chemotherapy treatment is mostly limited to temozolomide. In this paper, the authors review an emerging, novel drug called acid ceramidase, which targets glioblastoma. Its role in cancer treatment in general, and more specifically, in the treatment of glioblastoma, are discussed. In addition, the authors provide insights on acid ceramidase as a potential druggable target for glioblastoma. View Full-Text
Keywords: glioblastoma; acid ceramidase; acid ceramidase inhibitors; carmofur; radioresistance; radiation; sphingosine; sphingosine-1-phosphate; S1P glioblastoma; acid ceramidase; acid ceramidase inhibitors; carmofur; radioresistance; radiation; sphingosine; sphingosine-1-phosphate; S1P
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Nguyen, H.S.; Awad, A.J.; Shabani, S.; Doan, N. Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges. Pharmaceutics 2018, 10, 45.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top